Please login to the form below

Why aren't doctors using digital therapeutics?

The digital therapeutics market is set to reach almost $1 billion by 2026 as wearables and apps continue to play an important role in enhancing healthcare. However, adoption of these tools by healthcare professionals is comparatively low. Senior User Experience Consultant Stewart Anderson explains why.

In the digital age, the technology exists to better capture, analyse and share healthcare data to drive better patient outcomes, to improve their quality of life and ultimately to analyse aggregated, anonymised data to enhance our understanding of disease and population level outcomes.

With more than 300,000 healthcare apps available on the market today, it’s clear there is an abundance of healthcare technology available to meet a variety of patient, caregiver, and healthcare professional (HCP) needs. However, although HCPs are often initially excited about the digital therapeutics flooding the market, the uptake of these technologies is low.

This is not due to economic issues plaguing our healthcare systems. Recent analysis from IQVIA Institute for Human Data Science suggests that the use of digital health apps in five chronic disease patient populations could save the UK healthcare system an estimated £170 million per year. Despite these benefits, the National Health Service (NHS) has only just rolled out a 10-year, long-term plan to support a digitally enabled therapy assessment programme.

Across the Atlantic, the United States Food and Drug Administration (FDA) is also currently still in the pilot stage of its Software Precertification Program, which is redefining how the FDA regulates digital health devices. Although the consumer sector is using technology to solve customers’ challenges and enhance their experience, healthcare has fallen behind. This is in part due to the complexity of the healthcare industry, coupled with the high and sometimes fatal risks of failing to achieve the outcomes promised.

With 24 years of experience as a research and design professional, Stewart Anderson, Blue Latitude Health’s Senior User Experience Consultant, has honed his skills in digital service design, developing solutions that meet HCP and patient needs at the point of need. Here, he explains why doctors fail to prescribe digital health tools and how pharma companies can help to solve these challenges.

DOWNLOAD THE FULL INTERVIEW HERE

4th December 2019

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Three strategies for managing loss of exclusivity successfully
Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
What does the future hold for Medical Affairs?
Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health